Merck & Co. Aktie News

Weight loss drugs are the big story in the pharmaceutical industry today, but other opportunities exist, too. Bristol Myers Squibb isn't focused on weight loss, has an attractive yield, and continues to cover its dividend.

The U.S. Food and Drug Administration granted conditional approval for a Merck Animal Health pour-on treatment for the prevention and treatment of New World Screwworm, with farmers able to receive doses by December 20. U.S. cattle herds are at historic lows, pressuring beef prices, with the parasite from Mexico among multiple reasons for the decline in ranchers' livestock.

Merck spent a small fortune on the acquisition of Acceleron Pharma, and so far, it's paying off. Recent phase 2 data suggests the pharmaceutical giant could get even more bang for its buck.

Eli Lilly's GLP-1 drug became the world's best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones.

TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a renewed two-year contract with Merck, known as MSD outside of the United States and Canada. “Seeing Merck's teams use ASCEND to unravel disease biology, strengthen hypotheses, and make more evidence-driven decisions underscores the real scientific value AI can deliver....

PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today jointly announced that they have entered into a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda®1 (Pembrolizumab), i...

Telecom giant Verizon has the highest yield in the Dow at 6.8%. Energy Goliath Chevron currently offers a hefty 4.6% yield.

I see a generational opportunity in quality stocks, defined by high ROE, stable earnings growth, and low debt. Quality stocks have underperformed AI-driven leaders, creating rare relative value and attractive risk/reward for diversified, income-focused investors. My screen highlights 33 U.S. large caps with ≥25% ROE and ≥2% yield, many trading at compelling valuations.